I have a question about the independence of the reviews that are being done. I'm not talking about grandfathered chemicals now, but ones being brought onto the market. There's been much conversation with the witnesses we've had about the precautionary principle, about reverse onus being on the companies themselves.
Ms. Cooper, what's the state of affairs right now, from your perspective, in terms of new chemicals' being introduced, in terms of the rigour and the independence of that inquiry, and in terms of whether the precautionary principle is being applied sufficiently?